Article
RhuFab V2 safety and benefits maintained with continued dosing
Ft. Lauderdale-New results from the ongoing, Phase Ib/II open-label,randomized controlled trial of rhuFab V2 for the treatment of exudativeAMD show that a second course of treatment with up to four injection iswell-tolerated and provides ongoing biologic activity, reported JeffreyS. Heier, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
